Literature DB >> 9756785

In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.

K L Oakley1, C B Moore, D W Denning.   

Abstract

LY303,366 (LY) is a novel derivative of the echinocandin class of antifungal agents. The in vitro activities of LY, itraconazole (ITZ), and amphotericin B (AMB) were assessed against 60 Aspergillus isolates, including 35 isolates of A. fumigatus, eight isolates of A. terreus, eight isolates of A. flavus, eight isolates of A. niger and one isolate of A. nidulans. Four A. fumigatus isolates were resistant to ITZ. Susceptibility testing for all drugs was performed with a broth microdilution procedure. LY was tested in two media: antibiotic medium 3 (AM3) and Casitone with 2% glucose (CAS) with an inoculum of 2 x 10(3) spores/ml. ITZ and AMB were tested in RPMI 1640 with 2% glucose with an inoculum of 1 x 10(6) spores/ml. All tests were incubated at 37 degrees C for 48 h. A novel end point was used to determine a minimal effective concentration (MEC) for LY, i. e., almost complete inhibition of growth save a few tiny spherical colonies attached to the microplate. MICs were measured for ITZ and AMB with a no-growth end point. Ranges and geometric mean (GM) MECs were from 0.0018 to >0.5 and 0.0039 mg/liter and from 0.0018 to >0.5 and 0.008 mg/liter for LY in AM3 and LY in CAS, respectively. Differences between species were apparent, with A. flavus being significantly less susceptible to LY than any other species tested with both media (P </= 0.05). Ranges and GM MICs were from 0.125 to >16 and 0.7 mg/liter for ITZ and from 0.25 to 16 and 1.78 mg/liter for AMB. Minimal fungicidal concentrations (MFCs) were also determined for all drugs. GM MFCs were 0.018, 0.09, 19.76, and 12.64 mg/liter for LY in AM3, LY in CAS, ITZ, and AMB, respectively. LY in AM3 and LY in CAS were fungicidal for 86.7 and 68% of isolates, respectively (98% killing). In comparison, ITZ and AMB were fungicidal for 35 and 70% of isolates, respectively (99.99% killing). A reproducibility study was performed on 20% of the isolates. For 12 isolates retested, the MEC or MIC was the same or was within 1 dilution of the original value for 11, 11, 10, and 9 isolates for LY in AM3, LY in CAS, ITZ, and AMB, respectively. In conclusion, LY seems to be a promising antifungal agent with excellent in vitro activity against Aspergillus spp.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756785      PMCID: PMC105927     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.

Authors:  P E Verweij; K L Oakley; J Morrissey; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.

Authors:  O Uzun; S Kocagöz; Y Cetinkaya; S Arikan; S Unal
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Itraconazole resistance in Aspergillus fumigatus.

Authors:  D W Denning; K Venkateswarlu; K L Oakley; M J Anderson; N J Manning; D A Stevens; D W Warnock; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 4.  Therapeutic outcome in invasive aspergillosis.

Authors:  D W Denning
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

Review 5.  Aspergillosis.

Authors:  G P Bodey; S Vartivarian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

6.  In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.

Authors:  M A Pfaller; S A Messer; S Coffman
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

7.  In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.

Authors:  G G Zhanel; J A Karlowsky; G A Harding; T V Balko; S A Zelenitsky; M Friesen; A Kabani; M Turik; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

Review 8.  Echinocandins and pneumocandins--a new antifungal class with a novel mode of action.

Authors:  D W Denning
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790

9.  Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection.

Authors:  D W Denning; S A Radford; K L Oakley; L Hall; E M Johnson; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1997-09       Impact factor: 5.790

10.  In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp.

Authors:  C B Moore; D Law; D W Denning
Journal:  J Antimicrob Chemother       Date:  1993-12       Impact factor: 5.790

  10 in total
  14 in total

Review 1.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

2.  Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.

Authors:  F Ikeda; Y Wakai; S Matsumoto; K Maki; E Watabe; S Tawara; T Goto; Y Watanabe; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  A review of clinical experience with newer antifungals in children.

Authors:  Renee M Fallon; Jennifer E Girotto
Journal:  J Pediatr Pharmacol Ther       Date:  2008-07

4.  Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.

Authors:  A H Groll; D Mickiene; R Petraitiene; V Petraitis; C A Lyman; J S Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.

Authors:  Mamiko Miyazaki; Takaaki Horii; Katsura Hata; Nao-Aki Watanabe; Kazutaka Nakamoto; Keigo Tanaka; Syuji Shirotori; Norio Murai; Satoshi Inoue; Masayuki Matsukura; Shinya Abe; Kentaro Yoshimatsu; Makoto Asada
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

6.  Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis.

Authors:  J Roberts; K Schock; S Marino; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.

Authors:  S Tawara; F Ikeda; K Maki; Y Morishita; K Otomo; N Teratani; T Goto; M Tomishima; H Ohki; A Yamada; K Kawabata; H Takasugi; K Sakane; H Tanaka; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

8.  In vitro activity of anidulafungin against selected clinically important mold isolates.

Authors:  Zekaver Odabasi; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization.

Authors:  Carolina Serena; Montserrat Ortoneda; Javier Capilla; F Javier Pastor; Deanna A Sutton; Michael G Rinaldi; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 10.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.